Torixib

Etoricoxib

Acute & chronic symptomatic treatment of OA & RA. Ankylosing spondylitis (AS); acute gouty arthritis & pain including primary dysmenorrhoea & minor dental procedures.

OA 30 or 60 mg once daily. Not to exceed 60 mg daily. RA & AS 60 or 90 mg once daily. Not to exceed 90 mg daily. Acute pain & gouty arthritis, primary dysmenorrhoea Not to exceed 120 mg daily for 8 days. Minor dental procedures Not to exceed 90 mg once daily for 8 days. Mild hepatic insufficiency (Child-Pugh score 5-6) Not to exceed 60 mg once daily. Moderate hepatic insufficiency (Child-Pugh score 7-9) Not to exceed 60 mg every other day.

May be taken with or without food.

Hypersensitivity. Increased risk of CV disease eg, ischaemic heart disease & stroke. CHF (NYHA II-IV); established ischemic heart disease, peripheral arterial disease &/or cerebrovascular disease; uncontrolled HTN; active peptic ulceration or GI bleeding; inflammatory bowel disease. Developed signs of bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema or urticaria following ASA or other NSAIDs administration. Severe hepatic dysfunction (Child-Pugh score >9) & estimated CrCl <30 mL/min. Pregnancy & lactation. Childn & adolescents <16 yr.

Discontinue use at 1st appearance of skin rash, mucosal lesions or any other sign of hypersensitivity; persistent abnormal LFTs are detected. Not a substitute for aspirin in CV prophylaxis. Serious skin reactions eg, exfoliative dermatitis, SJS & TEN. Increased risk of GI ulceration, bleeding & perforation. History of serious adverse events & other risk factors associated w/ PUD eg, alcoholism, smoking, corticosteroid therapy. Significant risk factors for CV events eg, heart disease, HTN, hyperlipidaemia, DM; pre-existing edema or heart failure; acute asthmatic attacks, urticaria or rhinitis; cardiac dysfunction. May mask fever. Long-term use. Ensure adequate hydration prior to therapy. Closely monitor BP during therapy. Monitor renal function in patients w/ pre-existing significant renal impairment, uncompensated heart failure or cirrhosis. May affect ability to drive & use machines. Not recommended in advanced renal disease. Hepatic or renal dysfunction. Not recommended in women of childbearing potential. Lactation. Elderly or debilitated patients.

Thrombocytopenia; hypersensitivity reactions, anaphylactic/anaphylactoid reactions; hyperkalemia; anxiety, insomnia, confusion, hallucinations, depression, restlessness; dysgeusia, somnolence; blurred vision; CHF, palpitations, angina, arrhythmia; hypertensive crisis; bronchospasm; abdominal pain, oral & peptic ulcers, vomiting, diarrhoea; hepatitis, jaundice, hepatic failure; angioedema, pruritus, erythema, rash, SJS, TEN, urticaria, fixed drug eruption; renal insufficiency.

Increased prothrombin time INR w/ warfarin. Decreased plasma AUC w/ rifampin. Monitor for MTX-related toxicity. Diminished antihypertensive effects of diuretics, ACE inhibitors & AIIAs. Increased plasma lithium levels. Increased rate of GI ulceration or other complications w/ low-dose aspirin. Increased ethinyl estradiol conc. Increased estrogenic conc w/ post-menopausal hormone therapy.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

M01AH05 - etoricoxib ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, coxibs.

B